
BiotechTV - News From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
Sep 29, 2026
Stefanie Fluckiger-Mangual, CEO of TOLREMO Therapeutics, develops therapies against cancer treatment resistance. She explains the company’s distinct CBP/p300 inhibitor chemistry and encouraging phase 1 findings in resistant lung cancer. The conversation explores drug-tolerant cancer states, TT125-802’s safety profile, potential combinations with osimertinib, and TOLREMO’s broader plans in solid tumors and multiple myeloma.
AI Snips
Chapters
Transcript
Episode notes
Cancer Resistance Outlasts Effective Treatments
- Cancer treatment often fails because tumors adapt, not because effective therapies are unavailable.
- Stefanie Fluckiger-Mangual began studying this resistance mechanism at ETH Zurich 15 years ago.
TOLREMO Found CBP Through Phenotypic Screening
- TOLREMO and Cellcentric target the same CBP/p300 bromodomain, but their chemistries differ substantially.
- TOLREMO discovered CBP through a target-agnostic phenotypic screen rather than designing a conventional CBP inhibitor.
A Cleaner Safety Profile May Expand CBP Therapy
- First-generation CBP inhibitors showed efficacy but were limited by severe dose-limiting thrombocytopenia.
- TOLREMO's TT125802 produced no thrombocytopenia among 45 phase 1 patients.
